Prelude Therapeutics Incorporated (PRLD) is a Healthcare stock trading at $6.62 (as of 2026-08-21), with a market capitalization of $528.30M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company developing targeted cancer therapies for solid tumors and myeloid malignancies. Its pipeline includes PRT543 and PRT811 in Phase 1 trials, along with earlier-stage programs such as PRT1419 and other precision oncology candidates.
Understand Prelude Therapeutics Incorporated: how it makes money
Prelude Therapeutics develops precision oncology medicines, running early clinical trials for multiple drug candidates, and it may generate revenue through license agreements.
Near-term economics depend on progressing clinical programs that can later be monetized through licensing deals, while the company currently remains in early-stage development with limited disclosed revenue.
Business quality (Weak): Early-stage precision oncology pipeline with disclosed Phase 1 clinical activity, but the latest quarter shows no disclosed revenue and a very large operating loss.
Bull case
Phase 1 clinical activity is underway for PRT543 and PRT811 across select solid tumors and myeloid malignancies: This gives the company a measurable development track, including patient enrollment (65) and efficacy observations reported for monotherapy and combination therapy.
Combination therapy shows stronger response rates than monotherapy in the reported data: Overall Response Rate for Combination Therapy is 38.5%, versus Overall Response Rate for Monotherapy of 17.4%.
The trial data include reported complete and partial responses: Complete Responses for Combination Therapy are 3, and Partial Responses for Combination Therapy are 2.
Bear case
The company is still early in development, with multiple programs at Phase 1 or preclinic: Phase 1 results do not guarantee later-stage success, and preclinic programs (PRT-SCA2) add additional execution uncertainty.
Safety signals appear non-trivial in the reported treatment-emergent adverse events: Neutropenia Treatment-Emergent Adverse Events are 48%, Grade 3 or Higher Neutropenia is 46%, and Patients with Dose Interruptions due to Treatment-Emergent Adverse Events are 17.
Near-term financial scale appears limited based on the latest reported quarter: Revenue is shown as 0.0B for the quarter ending 2026-03-31, and Operating Margin is -309.5%.